

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2652)

**RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND A SUPERVISOR;
AND
PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR AND
A SUPERVISOR**

This announcement is made by CF PharmTech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(1), 13.51(2) and 13.51B of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Resignation of a Non-executive Director

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that Mr. CHEN Penghui (陳鵬輝) (“**Mr. CHEN**”) has resigned as a non-executive Director with effect from May 29, 2026 in order to devote more time to his other professional commitments.

Mr. CHEN has confirmed that he has no disagreement with the Company or the Board, and that there is no other matter relating to his resignation that needs to be brought to the attention of the Stock Exchange or the shareholders of the Company (the “**Shareholders**”).

The Board wishes to express its gratitude to Mr. CHEN for his valuable contributions during his tenure as a non-executive Director.

Resignation of a Supervisor

The Board further announces that Ms. ZHANG Jingjing (張晶晶) (“**Ms. ZHANG**”) has resigned as a supervisor (the “**Supervisor**”) and chairperson of the supervisory committee of the Company (the “**Supervisory Committee**”) with effect from May 29, 2026, in connection with her proposed nomination as an executive Director.

Ms. ZHANG has confirmed that she has no disagreement with the Company, the Board or the Supervisory Committee, and that there is no other matter relating to her resignation that needs to be brought to the attention of the Stock Exchange or the Shareholders.

In accordance with the Company Law of the People's Republic of China (the "PRC") and the articles of association of the Company (the "Articles of Association"), Ms. ZHANG will continue to perform her duties as Supervisor and chairperson of the Supervisory Committee until the new Supervisor is duly appointed at the forthcoming annual general meeting of the Company to be held on June 26, 2026 (the "AGM"), in order to maintain the minimum number of members of the Supervisory Committee required.

The Board wishes to express its gratitude to Ms. ZHANG for her valuable contributions during her tenure as Supervisor and chairperson of the Supervisory Committee.

Proposed Appointment of an Executive Director and a Supervisor

The Company is pleased to announce that: (i) at a Board meeting held on May 29, 2026, the Board resolved to nominate Ms. ZHANG as a candidate for executive Director; and (ii) at a Supervisory Committee meeting held on May 29, 2026, the Supervisory Committee resolved to nominate Mr. ZHENG Yao (鄭耀) ("Mr. ZHENG") as a candidate for Supervisor and chairperson of the Supervisory Committee, in each case for consideration and approval by the Shareholders at the AGM. The appointment of each of Ms. ZHANG and Mr. ZHENG will take effect upon approval by the Shareholders at the AGM.

The biographical details of Ms. ZHANG and Mr. ZHENG are as follows:

Ms. ZHANG Jingjing (張晶晶), aged 38, has served as Supervisor since November 2021 and as chairperson of the Supervisory Committee since December 2021, in each case until the effective date of her resignation referred to above. In addition to the role, Ms. ZHANG holds supervisorship in one subsidiary, namely Suzhou CF Health Technology Co., Ltd. (蘇州長風健康科技有限公司), and serves as general manager of another subsidiary, namely CF PHARMTECH XIAMEN LIMITED (長風藥業(廈門)有限公司), within the Group. She is principally responsible for the human resources management and marketing management of the Group, and currently serves as assistant general manager of the Company and deputy general manager of the Company's marketing center.

Prior to joining the Group, from July 2010 to September 2014, Ms. ZHANG served as a human resources specialist at Siyuan Electric Co., Ltd. (思源電氣股份有限公司). From September 2014 to April 2017, she worked at Shanghai Zhengda Investment Consulting Co., Ltd. (上海證大投資諮詢有限公司), a then subsidiary of Shanghai Zhengda Financial Information Service Co., Ltd. (上海證大金融信息服務有限公司). Since joining the Group in May 2017, she initially served as the Company's human resources manager, and has held her current positions at the marketing center since November 2024.

Ms. ZHANG obtained a bachelor's degree in biomedical engineering from Nanjing University of Aeronautics and Astronautics (南京航空航天大學) in the PRC in June 2010, and a master's degree in public administration from Shanghai Jiao Tong University (上海交通大學) in the PRC in June 2016. She also holds a board secretary qualification issued by the Shanghai Stock Exchange.

Subject to her appointment being approved at the AGM, the Company will enter into a service contract with Ms. ZHANG, the term of which shall commence from the date of approval at the AGM until the expiry of the term of office of the current session of the Board. Ms. ZHANG will be subject to retirement by rotation and re-election in accordance with the Articles of Association, and will be eligible for re-election upon the expiry of her term. Ms. ZHANG will not receive any director' fees in her capacity as a Director. Pursuant to her service contract, she will be entitled to a salary and additional benefits (including, without limitation, any incentives under any equity incentive scheme adopted by the Company from time to time), to be determined by the Board on the recommendation of the remuneration and appraisal committee of the Board, having regard to her experience, qualifications, duties and prevailing market conditions.

As at the date of this announcement, Ms. ZHANG holds (i) 72,905 shares of the Company (the “Shares”) through Suzhou Yuanchen Enterprise Management Center (Limited Partnership) (蘇州遠辰企業管理中心(有限合夥)); and (ii) 53,117 Shares through Suzhou Wolun Enterprise Management Center (Limited Partnership) (蘇州沃倫企業管理中心(有限合夥)), both of which are employee incentive platforms of the Company. Save as disclosed above, Ms. ZHANG does not have any interest in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

Ms. ZHANG has obtained the legal advice pursuant to Rule 3.09D of the Listing Rules on May 29, 2026 and will receive induction training and continuous professional development in accordance with the Listing Rules.

Save as disclosed above, Ms. ZHANG (i) has not held any directorship in any other public company the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement; (ii) has not held any other major appointments and professional qualifications; and (iii) does not hold any other position with the Company or any of its subsidiaries.

Mr. ZHENG Yao (鄭耀), aged 38, has approximately 15 years of experience in capital markets, investment management, financial auditing, fund management and corporate capital operations.

From July 2010 to April 2015, Mr. ZHENG served as an audit assistant at Gongzheng Tianye Certified Public Accountants (Special General Partnership) (公證天業會計師事務所(特殊普通合夥)). From May 2015 to July 2016, he served as a department head at Tianheng Certified Public Accountants (Special General Partnership) (天衡會計師事務所(特殊普通合夥)). From August 2016 to July 2017, he served as a senior manager at Zhongxi Certified Public Accountants (Special General Partnership) (中喜會計師事務所(特殊普通合夥)). From August 2017 to February 2019, Mr. ZHENG served as the head of compliance and risk control at Wuxi Jinchou Investment Management Co., Ltd. (無錫金籌投資管理有限公司). From March 2019 to July 2021, he served as an investment director at Wuxi Jintou Puyin Investment Management Co., Ltd. (無錫金投浦銀投資管理有限公司). Since August 2021, Mr. ZHENG has been serving as the chairperson of Wuxi Guolian Jintou Hehe Private Fund Management Co., Ltd. (無錫國聯金投和合私募基金管理有限公司).

Mr. ZHENG obtained a bachelor's degree in educational technology from Xi'an Polytechnic University (西安工程大學) in the PRC in July 2010 and an MBA from Nanjing University of Aeronautics and Astronautics (南京航空航天大學) in the PRC in November 2025. Mr. ZHENG is a member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會). He also serves as a council member of the Wuxi Xinwu District Venture Capital Promotion Association, an expert reviewer for a provincial key talent program, and an entrepreneurship mentor appointed by the Jiangyin High-Tech Zone Management Committee. Mr. ZHENG was recognized as a “Best Young Investor” on the 2026 Chinese Venture Rankings (融中榜).

Subject to his appointment being approved at the AGM, the Company will enter into a service contract with Mr. ZHENG, the term of which shall commence from the date of approval at the AGM until the expiry of the term of office of the current session of the Supervisory Committee. Mr. ZHENG will be eligible for re-election upon the expiry of his term. Mr. ZHENG will not receive any remuneration in his capacity as Supervisor. Pursuant to his service contract, he will be entitled to additional benefits (including, without limitation, any incentives under any equity incentive scheme adopted by the Company from time to time) at the discretion of the Board.

As at the date of this announcement, Mr. ZHENG does not have any interest in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. ZHENG (i) has not held any directorship in any other public company the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement; (ii) has not held any other major appointments and professional qualifications; and (iii) does not hold any other position with the Company or any of its subsidiaries.

Each of Ms. ZHANG and Mr. ZHENG has confirmed that he/she: (i) does not have any relationship with any other Director, Supervisor, member of senior management or substantial or controlling shareholder of the Company within the meaning of the Listing Rules; and (ii) has not been subject to any public sanction or disciplinary action by the China Securities Regulatory Commission, the Stock Exchange or any other regulatory or judicial authority.

Save as disclosed above, the Company is not aware of any other matter in relation to the proposed appointment of Ms. ZHANG and Mr. ZHENG that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor any other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.

A circular containing, among other matters, details of the proposed appointments of Ms. ZHANG and Mr. ZHENG, together with the notice of the AGM, will be dispatched to the Shareholders in due course.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing

Chairperson, Executive Director and Chief Executive Officer

Hong Kong, May 29, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors; Mr. CAI Lei and Dr. YI Hua as non-executive Directors; and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.